StockData
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Pacira BioSciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$1.46B
P/E (TTM)
103.8
Dividend yield
–

Pacira BioSciences statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison

Valuation

MeasurePacira BioSciencesIndustry median
Market Cap$1.45B$166.30M
Enterprise Value$1.56B$87.12M
PE Ratio103.8319.67
PS Ratio1.943.60
PB Ratio2.162.03
P/TBV Ratio3.952.31
P/FCF Ratio8.0717.44
P/OCF Ratio7.7213.32

Enterprise value

MeasurePacira BioSciencesIndustry median
EV / Sales2.092.43
EV / EBITDA14.8614.69
EV / EBIT78.5418.47
EV / FCF8.6920.97

Income (trailing twelve months)

MeasurePacira BioSciencesIndustry median
Revenue$746.16M$57.94M
Gross Profit$591.01M$90.47M
Operating Income$19.87M-$21.49M
Pretax Income$17.65M-$14.72M
Net Income$14.64M-$22.46M
EBITDA$105.03M-$17.14M
EPS (Diluted)$0.35-$0.83

Margins

MeasurePacira BioSciencesIndustry median
Gross Margin79.2%52.3%
Operating Margin2.66%-44.5%
Pretax Margin2.37%-13.0%
Profit Margin1.96%-39.2%
EBITDA Margin14.1%-31.3%
FCF Margin24.1%-8.85%

Returns

MeasurePacira BioSciencesIndustry median
Return on Equity (ROE)2.05%-53.2%
Return on Assets (ROA)1.05%-41.0%
Return on Invested Capital (ROIC)3.01%-32.2%
Return on Capital Employed (ROCE)1.77%-38.0%

Growth

MeasurePacira BioSciencesIndustry median
Revenue Growth (YoY)5.71%6.01%
FCF Growth (YoY)53.3%2.34%
Revenue Growth (3Y CAGR)2.89%2.25%
Revenue Growth (5Y CAGR)11.1%6.42%
EPS Growth (3Y CAGR)-22.2%-0.17%
EPS Growth (5Y CAGR)-45.5%3.77%

Balance sheet

MeasurePacira BioSciencesIndustry median
Cash & Short-Term Investments$251.03M$62.64M
Total Debt$363.12M$120.13M
Net Cash (Debt)-$112.09M$15.77M
Net Cash Per Share-$2.81$0.66
Equity (Book Value)$671.98M$48.61M
Book Value Per Share$16.86$1.36
Tangible Book Value$366.85M$23.01M
Working Capital$493.20M$75.09M

Financial position

MeasurePacira BioSciencesIndustry median
Current Ratio5.043.30
Quick Ratio3.142.39
Debt / Equity0.540.51
Debt / EBITDA3.463.35
Debt / FCF2.025.05
Net Debt / EBITDA1.072.22
Interest Coverage1.28-7.12

Cash flow (trailing twelve months)

MeasurePacira BioSciencesIndustry median
Operating Cash Flow$187.66M-$12.39M
Capital Expenditures-$8.15M-$1.07M
Free Cash Flow$179.52M-$20.34M
FCF Per Share$4.50-$0.42

Efficiency

MeasurePacira BioSciencesIndustry median
Asset Turnover0.540.38
Inventory Turnover1.102.67
Revenue Per Employee$900.08K$398.96K
Profits Per Employee$17.66K-$705.27K
Employee Count82974

Dividends and yields

MeasurePacira BioSciencesIndustry median
Earnings Yield1.01%-22.8%
FCF Yield12.4%-9.02%
Buyback Yield10.2%-0.73%
Shareholder Yield10.2%0.00%

Shares

MeasurePacira BioSciencesIndustry median
Shares Outstanding39,861,90058,139,000
Shares Change (YoY)-8.49%11.1%
Shares Change (QoQ)1.30%0.54%
Float37,438,60049,154,900
Shares Held by Insiders6.08%11.6%
Shares Held by Institutions110.3%59.4%

Taxes

MeasurePacira BioSciencesIndustry median
Income Tax$3.01M$89.00K
Effective Tax Rate17.1%20.5%

Scores

MeasurePacira BioSciencesIndustry median
Graham Number$11.52$17.04
Graham Upside-68.3%-44.3%
Altman Z-Score2.43-0.27
Piotroski F-Score84
Beneish M-Score-2.93-2.62

Calculated by StockData from Pacira BioSciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.